Exploring the effects of intermittent hypoxia on colorectal cancer
Exploratory Study of the Impact of Intermittent Hypoxia Intervention on Patients With Colorectal Cancer
NA · Capital Medical University · NCT06584318
This study is testing if breathing low oxygen levels for short periods can help people with colorectal cancer by boosting their immune system and slowing down tumor growth.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Capital Medical University (other) |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT06584318 on ClinicalTrials.gov |
What this trial studies
This study investigates the safety and efficacy of intermittent hypoxia intervention in patients diagnosed with colorectal cancer. The approach involves periodic exposure to low oxygen levels, which may enhance the body's immune response and potentially inhibit tumor progression. The study employs a non-randomized self-controlled design to assess the impact of this intervention on cancer outcomes. Previous animal studies have indicated promising results, suggesting that intermittent hypoxia could reduce inflammation and improve immune function in the context of cancer.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 to 65 with stage I or II colorectal cancer who can provide informed consent.
Not a fit: Patients with a history of significant comorbidities or recent cancer treatments may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could provide a novel therapeutic approach to enhance immune function and inhibit tumor growth in colorectal cancer patients.
How similar studies have performed: While the use of intermittent hypoxia has shown promise in animal models, this approach in human colorectal cancer patients is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with colorectal cancer between ages of 18 and 65 years. * Colorectal cancer stage Ⅰ,Ⅱ. * Subjects or their legally authorized representative can provide informed consent. Exclusion Criteria: * History of cardiovascular, cerebrovascular, dermatological, and hematological diseases. * History of pulmonary, hepatic, kidney, dermatologic and hematologic diseases. * History of pregnancy, hypertension, diabetes mellitus, obesity, sleep apnea and neurological disorders. * History of substance abuse. * Participating in other drug or medical device studies. * History of organ transplantation, including allogeneic stem cell and immune cell transplantation. * Recent severe infection within 4 weeks. * Received cancer treatment, including chemotherapy and radiotherapy, within 4 weeks. * Underwent major surgery within 28 days.
Where this trial is running
Beijing, Beijing Municipality
- Xuanwu Hospital, Capital Medical University — Beijing, Beijing Municipality, China (RECRUITING)
Study contacts
- Study coordinator: Yuan Wang, M.D.
- Email: wilma0106@163.com
- Phone: +86-13581567815
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Colorectal Cancer